Trophic Communications

Osivax announces publication in The Lancet Infectious Diseases of Phase 2a data for broad-spectrum influenza vaccine candidate, OVX836

The Phase 2a trial of OVX836 showed a notable signal of protection against influenza symptoms with an 84% level of protection compared to placebo. The vaccine candidate elicited significant humoral and cellular immune responses, highlighting its potential as a universal influenza vaccine.

SourceTrophic Communications·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateJul 27, 2023

CatalYm publishes data in Nature Communications describing gdf-15 as a central factor of anti-PD-1 resistance

Researchers discovered GDF-15 blocks LFA-1 dependent T cell recruitment into the tumor microenvironment, impairing immune responses to anti-PD-1 treatment. Visugromab improved T cell infiltration and increased tumor clearance with a synergistic effect

SourceTrophic Communications·JournalNature Communications·TypeExperimental study·DateJul 20, 2023

ImCheck publishes comprehensive overview of the development results of its first-in-class cancer immunotherapeutic targeting BTN3A to activate Vγ9Vδ2 T cells in Science Translational Medicine

ImCheck's ICT01 selectively activates Vγ9Vδ2 T cells through all three isoforms of BTN3A, overcoming prior limitations. The therapy demonstrates anti-tumor activity in solid and hematologic cancer models.

SourceTrophic Communications·JournalScience Translational Medicine·TypeRandomized controlled/clinical trial·DateOct 20, 2021

DiosCURE to develop highly specific single-chain antibodies against SARS-CoV-2

Researchers at DiosCURE developed lead candidates DIOS-202 and DIOS-203 with high potency and resistance to escape mutants. These multivalent single-chain antibodies target two distinct epitopes of the SARS-CoV-2 spike protein, rendering virions non-infectious.

SourceTrophic Communications·JournalScience·DateJan 12, 2021